




### Aerobic glycolysis supports biosynthesis




### Aerobic glycolysis supports biosynthesis




### Aerobic glycolysis supports biosynthesis




### Aerobic glycolysis supports biosynthesis



## Aerobic glycolysis supports biosynthesis




## Studies in *Drosophila* predict metabolic gene function in humans




- Metabolic regulators such as insulin, Tor, and myc are conserved in flies
- Analogous tissues regulate systemic metabolic processes
- Used to model diabetes, obesity, and heart failure
- Studies in *Drosophila* have predicted the function of mammalian homologs


### *Drosophila* larvae undergo rapid growth




### Aerobic glycolysis supports *Drosophila* larval growth




## The *Drosophila* Estrogen-Related Receptor promotes aerobic glycolysis



## Nuclear receptors are key metabolic regulators




## Estrogen-Related Receptors regulate metabolic function



- Mammalian ERRs are key metabolic regulators
- Promote fat metabolism and mitochondrial biogenesis
- Functional redundancy limits efficacy of genetic studies


## *dERR* mutants die during larval development

### *Drosophila* Life Cycle







### *dERR* mutants are energy starved and hyperglycemic




### Genomic and metabolomic analysis of *dERR* mutants




***dERR* mutants do not use sugar to generate energy**



***dERR* mutants display reduced expression of genes in the glycolytic pathway**



## *dERR* mutants display reduced expression of genes in the glycolytic pathway



## *dERR* directly regulates genes in the glycolytic pathway


**Glycolysis**

- HexA* -1.7
- Pgi* -5.2
- Pfk* -6.9
- Ald* -3.5
- Tpi* -3.1
- Gapdh2* -3.1
- Pgk* -3.7
- Pglym78* -3.8
- Eno* -1.9
- Pyk* -1.7

Predicted enzyme	Gene	Fold-Change	ERR binding site(s)
Hexokinase	CG3001 ( <i>HexA</i> )	-1.7	-913 aGAAGGTCA -128 TGAAGGTCA
Phosphoglucose isomerase	CG8251 ( <i>Pgi</i> )	-5.2	+871 gtAAGGTCA +908 ctgAGGTCA +1560 TGAAGGTCA
Phosphofructokinase	CG4001 ( <i>Pfk</i> )	-6.9	+1420 TGAAGGTCA
Aldolase	CG6058 ( <i>Ald</i> )	-3.5	-636 aGgAGGTCA +541 catAGGTCA +852 cCAAcGTCA
Triosephosphateisomerase	CG2171 ( <i>Tpi</i> )	-3.1	-678 cGAAGGTCA
Glyceraldehyde phosphate dehydrogenase	CG8893 ( <i>Gapdh2</i> )	-3.1	-847 aaAAGGTCA -489 TagAGGTCA -192 TatAGGTCA
Phosphoglycerate kinase	CG3127 ( <i>Pgk</i> )	-3.7	+16 gCAAGGTCA
Phosphoglycerate mutase	CG1721 ( <i>Pglym78</i> )	-3.8	-209 aaAAGGTCA +103 TgtAGGTCA +448 aCiAGGTCA
Enolase	CG17654 ( <i>Eno</i> )	-1.9	+1450 cgAAGGTCA +2316 aTaAGGTCA +2334 TagAGGTCA
Pyruvate kinase	CG7070 ( <i>Pyk</i> )	-1.7	-434 gtcAGGTCA +1002 TCAAGGTCA +2234 cGAAGGTCA


## dERR binds to a canonical site in *Pfk*

Glycolysis	
<i>HexA</i>	-1.7
<i>Pgi</i>	-5.2
<i>Pfk</i>	-6.9
<i>Ald</i>	-3.5
<i>Tpi</i>	-3.1
<i>Gapdh2</i>	-3.1
<i>Pgk</i>	-3.7
<i>Pglym78</i>	-3.8
<i>Eno</i>	-1.9
<i>Pyk</i>	-1.7




## dERR binds to a canonical site in *Pfk*


Glycolysis	
<i>HexA</i>	-1.7
<i>Pgi</i>	-5.2
<i>Pfk</i>	-6.9
<i>Ald</i>	-3.5
<i>Tpi</i>	-3.1
<i>Gapdh2</i>	-3.1
<i>Pgk</i>	-3.7
<i>Pglym78</i>	-3.8
<i>Eno</i>	-1.9
<i>Pyk</i>	-1.7




## The dERR binding site in *Pfk* is conserved across species




## *dERR* mutants display reduced expression of genes in the glycolytic pathway




### dERR is required for normal Pentose Phosphate Pathway Expression




### Lactate production is impaired in *dERR* mutants




## Lactate production is impaired in *dERR* mutants




## Proline is depleted in *dERR* mutants



### Proline is depleted in *dERR* mutants




### *dERR* mutant phenotypes suggest that *Drosophila* larvae use aerobic glycolysis







***dERR* mutant phenotypes suggest that *Drosophila* larvae use aerobic glycolysis**




***Drosophila* increase ~200-fold in mass during larval development**




## Genes that encode glycolytic enzymes are coordinately induced during embryogenesis



## The glycolytic transcriptional program is not properly induced in *dERR* mutants



## Conclusions



1. dERR establishes the metabolic state that supports juvenile growth
2. dERR directs a metabolic program related to the Warburg Effect during normal development
3. Mammalian ERR may contribute to cancer progression

## Human ERRs promote the Warburg Effect

Oncogene (2012), 1–8  
© 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12  
www.nature.com/onc



### ORIGINAL ARTICLE

### Regulation of glycolysis and the Warburg effect by estrogen-related receptors


Q Cai, T Lin, S Kamarajugadda and J Lu

Cancer cells typically display altered glucose metabolism characterized by a preference of aerobic glycolysis, known as the Warburg effect, which facilitates cell proliferation. Hypoxia-inducible factor (HIF) and oncoprotein Myc are two prominent transcription factors that drive glycolysis. Previously, we reported that the estrogen-related receptors (ERRs) act as cofactors of HIF and enhance HIF-dependent transcription of glycolytic genes under hypoxia. ERRs are orphan nuclear receptors and key regulators of energy metabolism by orchestrating mitochondrial biogenesis, fatty acid oxidation (FAO) and oxidative phosphorylation. Here, we show that ERRs also stimulate glycolysis under normoxia. ERRs directly bind to and activate promoters of many genes encoding glycolytic enzymes, and the ERR-binding sites in such promoters are essential for ERR-mediated transcriptional activation. ERRs interact with Myc, and the two factors synergistically activate transcription of glycolytic genes. Furthermore, overexpression of ERRs increases glycolytic gene expression and lactate production. Conversely, depletion of ERRs in cancer cells reduces expression of glycolytic genes and glucose uptake, resulting in decreased aerobic glycolysis and cell growth. Taken together, these results suggest that ERRs are important transcriptional activators of the glycolytic pathway and contribute to the Warburg effect in cancer cells.


Oncogene advance online publication, 4 June 2012; doi:10.1038/onc.2012.221

**Keywords:** aerobic glycolysis; Warburg effect; nuclear receptor; Randle cycle


What is the role of LDH in promoting larval growth?




*Ldh* mutants fail to produce lactate




## Pyruvate levels are elevated in *Ldh* mutants




## *Ldh* mutants fail to regenerate NAD<sup>+</sup>




### *Ldh* mutants die near the end of larval growth




### *Ldh* mutants grow at a normal rate



### *Ldh* mutants die near the end of larval growth



### Macromolecule biosynthesis is largely normal in *Ldh* mutants



*Ldh* mutants exhibit a modest increase in glycogen.

## The *Ldh* mutant phenotype is reminiscent of Glycogen Storage Disease Type XI

NCBI Resources How To

GTR: GENETIC TESTING REGISTRY

Conditions/Phenotypes Search


GTR Home > Conditions/Phenotypes > Glycogen storage disease XI

### Glycogen storage disease XI


**Synonyms:** GSD XI; LACTATE DEHYDROGENASE A DEFICIENCY  
**Modes of inheritance:** [Autosomal recessive inheritance](#) (HPO, OMIM, Orphanet)

**Summary**

Lactate dehydrogenase deficiency is a condition that affects how the body breaks down sugar to use as energy in cells, primarily muscle cells. There are two types of this condition: lactate dehydrogenase-A deficiency (sometimes called glycogen storage disease XI) and lactate dehydrogenase-B deficiency. People with lactate dehydrogenase-A deficiency experience fatigue, muscle pain, and cramps during exercise (exercise intolerance). In some people with lactate dehydrogenase-A deficiency, high-intensity exercise or other strenuous activity leads to the breakdown of muscle tissue (rhabdomyolysis). The destruction of muscle tissue releases a protein called myoglobin, which is processed by the kidneys and released in the urine (myoglobinuria). Myoglobin causes the urine to be red or brown. This protein can also damage the kidneys, in some cases leading to life-threatening kidney failure. Some people with lactate dehydrogenase-A deficiency develop skin rashes. The severity of the signs and symptoms among individuals with lactate dehydrogenase-A deficiency varies greatly. People with lactate dehydrogenase-B deficiency typically do not have any signs or symptoms of the condition. They do not have difficulty with physical activity or any specific physical features related to the condition. Affected individuals are usually discovered only when routine blood tests reveal reduced lactate dehydrogenase activity. [from GTR]




## Metabolomic analysis of *Ldh* mutants



*Ldh* mutants display the expected changes in lactate, pyruvate, and 2HG.




### Metabolomic analysis of *Ldh* mutants



Relatively few metabolites changed in response to loss of LDH activity

### *Ldh* mutants exhibit increased Glycerol-3-phosphate production



*Ldh* mutants also display increased G3P.

## ***Ldh* mutants exhibit increased GPDH expression**

Table 2. Metabolic Genes that are significantly misregulated in *Ldh* mutants

Gene Name	Function	Fold Change
Dot	UDP-glucuronosyl/UDP-glucosyltransferase	3.7
<b>Gpdh</b>	<b>Glycerol-3-phosphate dehydrogenase</b>	<b>3.6</b>
Ucp4B	Uncoupling protein 4B	3.3
CG34345	Oxoglutarate/iron-dependent dioxygenase	3.2
Orct	Solute Carrier Family	2.7
CG11208	2-hydroxyacyl-CoA lyase	2.7
Cyp6d5	Cytochrome P450	2.5
CG8008	Solute Carrier Family	2.4
MFS16	Solute Carrier Family 37A2	2.3
CG13248	Solute Carrier Family 7A4	2.3
PH4alphaMP	prolyl-4-hydroxylase-alpha MP	2.1
Cyp12a5	Cytochrome P450	-2.2
CG2065	short chain dehydrogenase	-2.5
Gpi1	N-acetylglucosaminyl transferase	-2.5
ImpL3	Lactate Dehydrogenase	-3.7
Sodh-2	Sorbitol dehydrogenase-2	-4.9

## **LDHA inhibition in pancreatic cancer cells also results in elevated G3P synthesis**

nature  
chemical biology

ARTICLE


PUBLISHED ONLINE: 1 AUGUST 2016 | DOI: 10.1038/NCHEM.2143

### **Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition**


Aaron Boudreau<sup>1,3</sup>, Hans E Purkey<sup>2,3</sup>, Anna Hitz<sup>3</sup>, Kirk Robarge<sup>2</sup>, David Peterson<sup>1</sup>, Sharada Labadie<sup>2</sup>, Mandy Kwong<sup>3</sup>, Rebecca Hong<sup>3</sup>, Min Gao<sup>3</sup>, Christopher Del Nagro<sup>3</sup>, Raju Pusapati<sup>1</sup>, Shuguang Ma<sup>4</sup>, Laurent Salphati<sup>4</sup>, Jodie Pang<sup>4</sup>, Aihe Zhou<sup>2</sup>, Tommy Lai<sup>5</sup>, Yingjie Li<sup>6</sup>, Zhongguo Chen<sup>6</sup>, Binqing Wei<sup>2</sup>, Ivana Yen<sup>7</sup>, Steve Sideris<sup>7</sup>, Mark McClelland<sup>8</sup>, Ron Firestein<sup>9</sup>, Laura Corson<sup>3</sup>, Alex Vanderbilt<sup>9</sup>, Simon Williams<sup>9</sup>, Anneleen Daemen<sup>10</sup>, Marcia Belvin<sup>3</sup>, Charles Eigenbrot<sup>11</sup>, Peter K Jackson<sup>3,12</sup>, Shiva Malek<sup>7</sup>, Georgia Hatzivassiliou<sup>3</sup>, Deepak Sampath<sup>3</sup>, Marie Evangelista<sup>1\*</sup> & Thomas O'Brien<sup>3\*</sup>

### LDH and G3P link in tumors *in vitro* and *in vivo*

*In vitro* LDHA inhibition:




*In vivo* LDH inhibition:



Boudreau A, Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nat Chem Biol. 2016 Aug 1. doi: 10.1038/nchembio.2143

### Glycerol 3-phosphate production could compensate for loss of LDH




### GPDH CRISPR deletions successfully made in the III and IV exon

**JaMT012**  
TCAAGGGCTTCGACAAGGCCGAGGGCGGCGG


**JaMT013**  
GCCGATCTGATCAGCAGGTGTTACGgtaagtg



II Chromosome:




CRISPR A10	deletion of 19	JaMT012	TCAAGGGCTTCGACAAGGCCGAGGGCGGCGG
CRISPR B26	deletion of 2	JaMT012	TCAAGGGCTTCGACAAGGCCGAGGGCGGCGG
CRISPR B18	deletion of 7	JaMT013	GCCGATCTGATCAGCAGGTGTTACGgtaagtg

### GPDH CRISPR mutants exhibit significant decreases in glycerol-3-phosphate accumulation






**GPDH is required to maintain larval redox balance*****Gpdh* mutants grow at a normal rate**

### Functional significance of GPDH when LDH is mutated




*\*Expect lethality if GPDH is compensating for LDH loss by regenerating NAD<sup>+</sup>*





## *Gpdh*; *Ldh* double mutants exhibit a synthetic lethal phenotype



## The relationship between LDH and GPDH was observed in tumors nearly 60 years ago

### Low Levels of Soluble DPN-linked $\alpha$ -Glycerophosphate Dehydrogenase in Tumors\*

GEORGE E. BOXER AND CARL E. SHONK

(Merck Institute for Therapeutic Research, Rahway, N.J.)

#### GPDH AND LDH ACTIVITY OF NORMAL TISSUES

The ranges indicated refer to the highest and lowest values observed. The single values are averages of three or less determinations.

Species	Tissue	GPDH (units/mg)	LDH (units/mg)	LDH/GPDH
Rat	Liver	90-225	239-322	1.3-2.6
	Muscle	176-639	472-1528	2.7-3.4
	Lymph nodes	75-150	100-200	0.5-4.0
	Adipose tissue	50	85	1.5
Mouse	Liver	112-181	294-500	1.6-3.4
	Kidney	158	182	0.8
	Spleen	28	22	0.8
	Muscle	185-268	1350-1514	3.1-7.2
Hamster	Liver	192-245	126-167	0.55-0.68
	Muscle	145-197	79-85	0.48-0.55
Human (I.M. in cortisonized hamsters)	Liver*	138	83	0.67
	Kidney*	100-119	62-81	0.62-0.68
	Spleen	64	34	0.53
	Muscle	158-274	964-1585	5.0-7.0

\* Data for hamsters under cortisone treatment.


Cancer Research (1960) 20:85-91

#### GPDH AND LDH ACTIVITY IN TRANSPLANTED RAT AND HAMSTER TUMORS AND OF HUMAN TUMORS GROWING IN CORTISONIZED HAMSTERS

Tumors	GPDH (units/mg)	LDH (units/mg)	LDH/GPDH
Rat:			
Murphy lymphosarcoma	8	94	12
Walker 256	8	278	35
Jensen sarcoma	3	123	41
Hamster:			
Fortner, pancreatic #1*	3	470	157
Fortner, small bowel carcinoma*	5	422	84
Bashford carcinoma*	14	332	24
Crabb sarcoma	> 0.7	660	< 900
Human (I.M. in cortisonized hamsters):			
Adenocarcinoma #1	7	298	43
Epidermoid carcinoma #3	4	145	36
Bronchiogenic carcinoma	25	234	9
Sarcoma #1	5	210	42

The values represent averages of results obtained on two or more individual tumors, except those indicated by an asterisk, which were obtained on single tumors.






**Tennessee Lab**  
Hongde Li  
Arthur Luhur  
Geetanjali Chawla  
Alex Hurlburt  
Maria Sterrett  
Rose Massey  
Nader Mahmoudzadeh  
Usman Ashraf  
Samantha St. Clair  
Alondra Flores

**University of Utah**  
Carl Thummel  
James Cox

**Indiana University**  
Dr. Jonathan Karty

  
**BDSC**  
**DGRC**  
**Flybase**

**Support**  
R35 MIRA (NIH; NIGMS)  
R00 Pathway to Independence Award (NIH; NIGMS)  
Michigan Regional Comprehensive Metabolomics Core Facility (P/F Award)  
Indiana CTSI